Literature DB >> 8792854

Acute-phase plasma proteins in gastric cancer: association with metastatic potential and prognosis.

K Ogoshi1, T Tajima, T Mitomi, M Tsuda, M Yamamura.   

Abstract

We evaluated the possibility that acute-phase plasma proteins such as alpha 1-antichymotrypsin (ACT) and immunosuppressive acidic protein (IAP) might be useful predictors of lymph node metastasis and prognosis in patients with gastric cancer. Both ACT and IAP levels generally increased according to the pTNM stage. Patients with both abnormal IAP and ACT levels showed a high risk of lymphatic and hepatic metastasis as well as peritoneal dissemination, with a resultant poor prognosis. Patients who had abnormal IAP levels with or without abnormal ACT levels had a significantly higher risk of lymph node metastasis, as well as more invasive tumors and a worse prognosis than those who had normal IAP levels with or without abnormal ACT levels. In combination group 4 [IAP(+) ACT(-) vs. IAP(-) ACT(+)] lymphatic metastasis was seen more often with isolated IAP(+) (76.4%) than with ACT(+) (52.9%) (p < 0.0045), especially in the subgroup of poorly differentiated adenocarcinoma (POR; p < 0.0177). However, this does not demonstrate that ACT(+) is a protective factor against lymphatic invasion, because the results of combination group 6 [IAP(-) ACT(+) vs. IAP(-) ACT(-)] show that isolated ACT(+) is also significantly related to lymphatic metastasis (p < 0.001). The same is true for the subgroup of signet ring cell carcinomas (p = 0.038), but it has not been tested versus the POR subgroup.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8792854     DOI: 10.1159/000217990

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  2 in total

1.  Perioperative allogenic blood transfusion and serum levels of immunosuppressive acidic protein in patients undergoing resection of colorectal carcinoma.

Authors:  T Iwanaga; H Suzuki
Journal:  Dig Dis Sci       Date:  1999-08       Impact factor: 3.199

2.  Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303).

Authors:  Andrew S Roberts; Michael J Campa; Elizabeth B Gottlin; Chen Jiang; Kouros Owzar; Hedy L Kindler; Alan P Venook; Richard M Goldberg; Eileen M O'Reilly; Edward F Patz
Journal:  Cancer       Date:  2011-06-28       Impact factor: 6.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.